Amendment No.

CHAMBER ACTION

Senate House

•

Representative Glorioso offered the following:

1 2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

Amendment (with title amendment)

Between lines 81-82 and insert:

Section 2. Subsection (5) is added to section 627.4239,, Florida Statutes, to read:

627.4239 Coverage for use of drugs in treatment of cancer.--

(4) ANNUAL REPORTS.--

(a) Where coverage for routine patient care costs associated with care provided in a phase 1, 2, 3, or 4 cancer clinical trial is denied, a carrier shall, after consulting academic and community oncologists involved in cancer care and clinical research, submit to the office of insurance regulation in a format prescribed by rule, an annual report that shall include:

898619

Approved For Filing: 4/23/2009 1:54:37 PM Page 1 of 3

Amendment No.

- 1. The number of denials for coverage of routine patient care cost as defined in paragraph (c) in cancer clinical trials.
- 2. A comparison of the costs of routine patient care provided in the trials in question compared to the costs of standard therapies for the same diagnosis.
- (b) The annual reports required under paragraph (a) shall be provided by the Office of Insurance Regulation to the Governor, the Senate President, the Speaker of the House of Representatives, and the Secretary of the Agency for Health Care Administration no later than 30 days prior to the regular legislative session.
- (c) For purposes of this section, the term "routine patient care cost" means physician fees, laboratory expenses, and expenses associated with the hospitalization, administration of treatment, and evaluation of a patient during the course of treatment which are consistent with usual and customary patterns and standards of care incurred whenever an enrollee, subscriber, or insured receives medical care associated with an approved cancer clinical trial, and which would be covered if such items and services were provided other than in connection with an approved cancer clinical trial but does not include the direct cost of the clinical trial.

HOUSE AMENDMENT Bill No. CS/CS/HB 675

Amendment No.

45	TITLE AMENDMENT
46	Remove line(s) 12 and insert:
47	credibility criteria for the rate adjustment; amending s
48	627.4239, F.S.; providing annual reporting requirements;
49	providing a definition; providing an
50	